Our management

Said was appointed Chief Executive Officer in July 2007. Said was Chairman and Chief Executive of the Hikma’s group holding company from 1994 to 2003 and Minister of Health for the Hashemite Kingdom of Jordan from 2003 to 2006.

During his thirty two years at Hikma, Said has undertaken several executive roles which have provided him with extensive experience in each functional area of Hikma’s global generic pharmaceuticals business and in the broader strategic leadership of an international entrepreneurial organisation. Said has played a key role in the development of the group strategy, including the acquisition of West-Ward Pharmaceuticals in the USA and the development of the Injectables business in Europe and the MENA region. Under Said’s leadership, Hikma’s facilities in the USA, Jordan and Portugal received US FDA approval, the leading international pharmaceutical regulatory standard.

Said has a degree in industrial engineering from Purdue University and an MBA from INSEAD.

Mazen was appointed group Executive Vice-Chairman and MENA CEO in 2005. During his 28 years’ service at Hikma, he has held an extensive range of positions within the Group starting as a medical representative and working in different capacities including Chairman and CEO of Hikma Pharmaceuticals Limited, a major group operational and holding company.

As Chief Executive of MENA, Mazen is leading the geographical expansion and consolidation of Hikma in MENA region and the formation of strategic business partnerships. Mazen is the executive lead of Hikma’s corporate social responsibility and business integrity programs.

Mazen holds a BA in Business Administration from the Lebanese American University and an AMP from INSEAD. He has served as the President of the Jordanian Association of Manufacturers of Pharmaceuticals and Medical Appliances.

Ali joined Hikma as director of Hikma Pharma Limited in 1981 and has held various directorships within the Group.   Ali brings great financial experience to the Board as well as an in-depth knowledge of the MENA region and Hikma Pharmaceuticals.  Ali was a founder of The Capital Bank of Jordan, which offers commercial and investment banking services, and served as Chief Executive Officer of the Bank until 2007.

Ali has a degree in Mechanical Engineering from the University of Southern California and an MBA from INSEAD.

Sir David brings to Hikma wide experience in financial matters, corporate governance, public affairs, and the development of listed companies. Sir David is a former Lord Mayor of London, and has held many senior positions in UK financial institutions including serving as Chairman of Brewin Dolphin Holdings PLC and Arden Partners PLC. He is a past President of The Crown Agents Foundation and a former regional director of Lloyds Bank plc.

Michael has over 30 years’ experience in the pharmaceutical industry, holding senior executive positions with Pfizer and Merck. Michael was Chief Executive Officer of SkyePharma PLC from November 1998 to March 2006 and prior to that was Chairman, President and Chief Executive Officer of Faulding. He has held a number of non-executive and advisory positions across the pharmaceutical industry.

Michael has a Bachelor of Pharmacy degree from Sydney University, and his MBA degree from Rutgers University, New Jersey.

Breffni is a chartered accountant with over 30 years of experience in public practice, including significant international responsibilities. Breffni served as the Managing Partner of the Audit and Business Advisory practice of Arthur Andersen in Ireland and as Director of Risk Management of Andersen's audit practice in Middle East, India, Africa and the Nordic countries. Breffni has extensive experience in financial reporting, international operations, corporate governance and general financial and commercial matters. He is a former non-executive director of Irish Life and Permanent plc. He is considered by the Board to have recent and relevant financial experience.

Breffni holds a Masters degree in Economic Science from the University College, Dublin and is a Chartered Accountant.

Ron has spent over 30 years in the international pharmaceutical industry, including roles as President of International Operations at Searle and Vice President of Clinical and Scientific Affairs at Pfizer. His extensive experience includes leading companies as CEO and acting as an adviser to companies in the pharmaceutical industry.  He also advises companies involved in nanotechnology and in the information technology business sectors.

Ron was formerly President and Chief Executive Officer of Unimed Pharmaceuticals, Inc. and eXegenics Inc. He is a trustee of Thunderbird School of Global Management, which is ranked by the Financial Times as the premier international business school.

Ron has a PhD from the University of Georgia and a MS and BS from the University of Memphis.